Lead product GelrinC®, a hydrogel synchronized erosion and resorbable implant, the only restorative product for knee ...

Chronic back pain often starts small but gradually affects every part of life. Experts explain why it worsens and why ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

The latest announcement is out from Immix Biopharma ( (IMMX) ).

The Wyss Institute is proud to welcome three new Associate Faculty members: Ahmad (Mo) Khalil, Ph.D., Jarad Mason, Ph.D., and Chao-ting (Ting) Wu, Ph.D. Each has a history of collaborating with the ...

Investing.com -- Lyell Immunopharma Inc (NASDAQ:LYEL) stock rose 4.2% in premarket trading Monday after the clinical-stage biotech company reported promising data from its cancer therapy trials.

EUDA Health Holdings Limited (NASDAQ: EUDA) ('EUDA” or the 'Company”), a Singapore-based leading non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced its ...

Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented ...

The first 100 bases of many genes show excess mutations, revealing a major genomic weak spot that shapes disease risk and ...

The World Tourism Network played a central role at MIMTC 2025, highlighting the rising integration of medical, wellness, and ...

About NEXICART-2 NEXICART-2 (NCT06097832) is an ongoing multi-site U.S. Phase 2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational design ...

Indo–Italian medical consensus sounds alarm on paediatric sarcoma; experts urge action on early diagnosis: Our Bureau, Bengaluru Monday, December 8, 2025, 13:40 Hrs [IST] IndoIt ...